E. Robert Wassman

NeuroPointDx, a division of Stemina Biomarker Discovery, has appointed E. Robert Wassman as its medical director. Wassman has acted as chief medical officer (CMO) for several companies in the genetic testing, biomarker discovery, and diagnostic development space. He previously served as CMO of Lineagen from 2015 to 2017. Before that, he served as CMO at Rosetta Genomics from 2012 to 2015. Wassman has also previously served as CMO at other companies in the personalized medicine space over the past 35 years, including Genzyme Genetics, Celula, Ambry Genetics, and Alfigen.